Anexigen is Drug Discovery in United States that focus on developer business. Founded in 2018. They cover business area such as developer, novel method, composition, antimicrobial threat, novel antibacterial agent, activity, drug-resistant bacteria, biomedical interest, functional screening, dna-encode peptide-base library, any Gram-negative pathogen, novel antibiotic chemical scaffold, clinician, patient, drug-resistant pathogen, its platform.
2018
( 6 years old in 2024 )
Developer
-
11099 North Torrey Pines Road
Suite 290
La Jolla, CA 92037
United States
Private
developernovel methodcompositionantimicrobial threatnovel antibacterial agentactivitydrug-resistant bacteriabiomedical interestfunctional screeningdna-encode peptide-base libraryany Gram-negative pathogennovel antibiotic chemical scaffoldclinicianpatientdrug-resistant pathogenits platform
* We use standard office opening hours in near Anexigen's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Anexigen is Drug Discovery business from United States that founded in 2018 (6 years old in 2024), Anexigen business is focusing on Developer.
Anexigen headquarter office and corporate office address is located in 11099 North Torrey Pines Road Suite 290 La Jolla, CA 92037 United States.
Anexigen was founded in United States.
In 2024, Anexigen is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Anexigen, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
